TY - JOUR
T1 - Primary CNS lymphoma treated with radiotherapy in Japan
T2 - a survey of patients treated in 2005–2009 and a comparison with those treated in 1985–2004
AU - Shibamoto, Yuta
AU - Sumi, Minako
AU - Onodera, Shunsuke
AU - Matsushita, Haruo
AU - Sugie, Chikao
AU - Tamaki, Yukihisa
AU - Onishi, Hiroshi
AU - Abe, Eisuke
AU - Koizumi, Masahiko
AU - Miyawaki, Daisuke
AU - Kubota, Seiji
AU - Ogo, Etsuyo
AU - Nomiya, Takuma
AU - Takemoto, Mitsuhiro
AU - Harada, Hideyuki
AU - Takahashi, Ippei
AU - Ohmori, Yoshio
AU - Ishibashi, Naoya
AU - Tokumaru, Sunao
AU - Suzuki, Kazunori
N1 - Funding Information:
This work was supported in part by a research grant from the Japanese Ministry of Education, Culture, Sports, Science and Technology. The authors wish to thank Drs. Toshinori Soejima, Shoichi Fukuda, Shiho Ayakawa, Masayuki Araya, Hiroaki Suefuji, Yuzuru Suzuki, Hidehiro Eto, Yuko Watanabe, Mutsuyuki Hattori, and Yoshimi Horikawa for their help in collecting data.
Publisher Copyright:
© 2013, Japan Society of Clinical Oncology.
PY - 2014/10/16
Y1 - 2014/10/16
N2 - Conclusions: Although patient backgrounds differed among the study periods, recent trends were a high patient age, better PS, avoidance of extensive tumor resection, more frequent use of chemotherapy, and improved survival. The recent improvement in survival may be due to improvements in second-line treatment and supportive care.Background: The aim of our study was to analyze changes over time in the characteristics, treatment, and outcome of patients with primary central nervous system lymphoma (PCNSL).Methods: Data on 315 patients with histologically proven PCNSL undergoing radiotherapy between 2005 and 2009 were collected from 20 Japanese institutions using a questionnaire. These data were then compared with data on 273 patients treated during the period 1995–2004 and those on 466 patients treated during the period 1985–1994.Results: In terms of patient and tumor characteristics, we found a significant increase in mean patient age in the 2005–2009 period compared to the 1985–2004 period (63 vs. 58–59 years, respectively) and in the percentage of patients with better performance status (PS) during the 2005–2009 period compared with the 1995–2004 period (World Health Organization PS 0–2: 73 vs. 65 %, respectively). Regarding treatment, relative to the 1995–2004 period, significant changes in the 2005–2009 period were (1) decreased rate of attempting tumor resection (23 vs. 44 %); (2) increased use of chemotherapy (78 vs. 68 %), and (3) increased use of methotrexate (MTX)-containing regimens (84 vs. 53 %). The 5-year overall survival rates were 15.3, 30.1, and 36.5 % for patients seen during the 1985–1994, 1995–2004, and 2005–2009 periods, respectively, but relapse-free survival did not improve between the 1995–2004 and 2005–2009 periods (26.7 vs. 25.7 % at 5 years, respectively). Patients receiving MTX-containing chemotherapy had 5-year survival rates of 19, 50, and 44 % during these three periods, respectively.
AB - Conclusions: Although patient backgrounds differed among the study periods, recent trends were a high patient age, better PS, avoidance of extensive tumor resection, more frequent use of chemotherapy, and improved survival. The recent improvement in survival may be due to improvements in second-line treatment and supportive care.Background: The aim of our study was to analyze changes over time in the characteristics, treatment, and outcome of patients with primary central nervous system lymphoma (PCNSL).Methods: Data on 315 patients with histologically proven PCNSL undergoing radiotherapy between 2005 and 2009 were collected from 20 Japanese institutions using a questionnaire. These data were then compared with data on 273 patients treated during the period 1995–2004 and those on 466 patients treated during the period 1985–1994.Results: In terms of patient and tumor characteristics, we found a significant increase in mean patient age in the 2005–2009 period compared to the 1985–2004 period (63 vs. 58–59 years, respectively) and in the percentage of patients with better performance status (PS) during the 2005–2009 period compared with the 1995–2004 period (World Health Organization PS 0–2: 73 vs. 65 %, respectively). Regarding treatment, relative to the 1995–2004 period, significant changes in the 2005–2009 period were (1) decreased rate of attempting tumor resection (23 vs. 44 %); (2) increased use of chemotherapy (78 vs. 68 %), and (3) increased use of methotrexate (MTX)-containing regimens (84 vs. 53 %). The 5-year overall survival rates were 15.3, 30.1, and 36.5 % for patients seen during the 1985–1994, 1995–2004, and 2005–2009 periods, respectively, but relapse-free survival did not improve between the 1995–2004 and 2005–2009 periods (26.7 vs. 25.7 % at 5 years, respectively). Patients receiving MTX-containing chemotherapy had 5-year survival rates of 19, 50, and 44 % during these three periods, respectively.
KW - Chemotherapy
KW - Lymphoma
KW - Primary CNS lymphoma
KW - Radiotherapy
KW - Soluble interleukin-2 receptor
UR - http://www.scopus.com/inward/record.url?scp=84919402771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84919402771&partnerID=8YFLogxK
U2 - 10.1007/s10147-013-0644-4
DO - 10.1007/s10147-013-0644-4
M3 - Article
C2 - 24297187
AN - SCOPUS:84919402771
SN - 1341-9625
VL - 19
SP - 963
EP - 971
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 5
ER -